Viyash Scientific (512529) Q4 02/03 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 02/03 earnings summary
29 Oct, 2026Executive summary
FY ended Mar. 31, 2003 closed with a net loss of Rs 126,432, compared with Rs 97,462 in FY02; no equity dividend recommended.
Balance sheet was dominated by Rs 54.50m in loans and advances, against Rs 54.93m in total funds.
Financial highlights
Dividend income was Rs 8 and administrative and other expenses were Rs 126,440; net loss was Rs 126,432 versus Rs 97,462 in FY02.
Loss before tax and loss after tax were both Rs 126,432; no tax provision was recorded.
Administrative and other expenses included Rs 57,877 of share issue expenses written off, equal to the prior-year charge.
Key financial ratios and metrics
Earnings per share was listed as NIL; dividend rate was NIL.
Paid-up equity capital was Rs 40.00m; reserves and surplus were Rs 14.93m, including Rs 13.16m share premium.
Latest events from Viyash Scientific
- FY1997-98 profit was Rs 36,882; earnings were retained and Rs 10 crore borrowing authority proposed.512529
Q4 97/98 - Investment-sale gains lifted FY99 PAT to ₹1.653m; earnings were retained and no dividend recommended.512529Q4 98/99
- FY02 loss narrowed, but Rs 55.57m in advances remained subject to confirmation.512529Q4 01/02
- ₹295.51 lakh FY04 net profit; growth guidance exceeded 50% post-amalgamation.512529Q4 03/04
- FY05 profit rose as capacity expansion and new markets became central priorities.512529Q4 04/05
- FY06 growth and new capacity supported expansion, while rising input costs remained a key risk.512529Q4 05/06
- Sales climbed 23%; adjusted PAT rose 32% as R&D and veterinary APIs set the growth agenda.512529Q4 06/07
- Transchem expanded the business as currency pressure and higher costs squeezed profit.512529Q4 07/08
- Standalone profit grew, but consolidation swung to a ₹1,466 lakh net loss.512529Q4 08/09